Pharma stocks slip
Shares in drug companies fell after President Trump signalled possible tariffs on imported medicines, with investors starting to price in disruption even before any formal order. The market move reflects sectoral sensitivity to policy signals that can change supply‑chain costs and access to foreign suppliers. (jainam.in)
Drugmakers’ shares fell on April 9, 2025, after President Donald Trump said a “major” tariff on imported medicines was coming. (nbcnews.com) Reuters reported the selloff hit companies across the United States and Europe, after Trump repeated the threat a day earlier and broader country tariffs also took effect. Some United States drug stocks later pared losses after Trump paused some reciprocal tariffs for 90 days, but the sector-specific drug threat remained. (nbcnews.com) (cnbc.com) The White House had initially left pharmaceuticals out of the April 2, 2025 tariff package, then Trump said on April 8 that separate drug tariffs would arrive “very shortly.” That shift changed the market’s read on a sector that had been treated as temporarily spared. (fiercepharma.com) (biopharmadive.com) Pharmaceutical tariffs matter because the United States buys a huge volume of finished medicines and ingredients from abroad. United States pharmaceutical imports totaled about $212.7 billion in 2024, according to trade data compiled from the United Nations Comtrade database. (tradingeconomics.com) The supply chain is global long before a pill reaches a pharmacy shelf. The Association for Accessible Medicines said generic and biosimilar drugs made up 90 percent of United States prescriptions in 2024, while an industry-backed United States-India report said 87 percent of Food and Drug Administration-registered plants making generic active pharmaceutical ingredients are outside the United States. (accessiblemeds.org) (ipa-india.org) That is why investors reacted before any formal tariff order was published. An Ernst & Young analysis reviewed by Reuters found a 25 percent tariff on pharmaceutical imports would raise United States drug costs by nearly $51 billion a year and could lift prices by as much as 12.9 percent if companies passed the increase through. (nbcnews.com) Drugmakers and their trade groups have argued tariffs could disrupt supply and raise costs for patients. Trump said the threat was meant to push manufacturing back to the United States, framing import reliance as a national security problem. (biopharmadive.com) (thehill.com) India sits near the center of that debate because it is a major supplier of lower-cost medicines to the United States. Industry and trade reports cited in 2025 said Indian companies supply roughly 40 percent of generic drugs used in the United States, making any tariff fight a direct issue for pharmacies, hospitals, and insurers. (fortuneindia.com) (ctmirror.org) The immediate market move was about uncertainty as much as policy. Once Trump signaled that pharmaceuticals were no longer off-limits, investors started pricing in higher costs, supply-chain rewiring, and a sector that could no longer count on tariff exemptions. (nbcnews.com) (fiercepharma.com)
